Related Experiment Video

Updated: Mar 23, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?

Reza Mehrazin1, Che-Kai Tsao2, John Sfakianos1

  • 1Department of Urology & Oncological Science, Icahn School of Medicine at Mount Sinai, New York, NY.

Urologic Oncology
|March 22, 2016
PubMed

Insights

Adjuvant therapy for renal cell carcinoma (RCC) after surgery has not shown clear benefits. Future research should focus on molecular targets to improve outcomes for this lethal cancer.

Area of Science:

  • Oncology
  • Nephrology
  • Translational Research

Background:

  • Adjuvant therapy for renal cell carcinoma (RCC) post-surgery is under investigation.
  • Current systemic therapies lack definitive evidence of benefit.
  • Existing guidelines do not recommend adjuvant therapy for RCC.

Purpose of the Study:

  • To review randomized studies on adjuvant treatments for renal cell carcinoma (RCC).
  • To identify potential future directions for RCC treatment development.
  • To highlight the need for improved therapeutic strategies for RCC.

Main Methods:

  • Systematic review of randomized clinical trials on adjuvant therapy for RCC.
  • Analysis of systemic therapies with diverse mechanisms of action.
  • Evaluation of study outcomes and statistical significance.

Main Results:

  • Numerous studies evaluated adjuvant therapies for RCC.
  • No adjuvant therapy has demonstrated a definitive survival benefit to date.
  • Current evidence does not support the routine use of adjuvant therapy in RCC.

Conclusions:

  • Further understanding of RCC molecular pathogenesis is crucial.
  • Identification of novel therapeutic targets and biomarkers is needed.
  • Future efforts should focus on developing targeted and personalized adjuvant treatments for RCC.
Keywords:
Adjuvant therapyClinical trialsKidney cancerNephrectomyTyrosine kinase inhibitor

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.6K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
459
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K